Selecting the right system for metabolite identification

Jul 14, 2023 | Blogs, LC, Pharma, SCIEX OS software, ZenoTOF 7600 system | 0 comments

Read Time: 3 minutes

So, you need a new liquid chromatography-mass spectrometry (LC-MS) system for your metabolite identification (metID) studies, and you are not sure which option is right for you. This blog provides an overview of the metID solutions offered by SCIEX, so you can make the best decision for your organization.

This is the first in a series of blogs intended to help you choose a system that meets your pharmaceutical research and development needs. We hope you find their guidance useful.

Let’s start with a simple question: Which of the following would help you sleep well at night?

  • A: knowing your batch of samples will be complete by your deadline
  • B: a clear identification of the site of metabolism for those extra complex samples

We have great news for you: SCIEX has solutions for enabling both A and B. Let’s take a closer look.

Scenario A
Let’s say you are looking for a system that will run larger batches of samples, and your analytes typically fragment well using collision-induced dissociation (CID), allowing confident identification of the site of metabolism without the need for additional confirmatory testing.

For a complex analysis, the requirements are relatively straightforward, and the priorities are probably ease of use and a robust system that does the job day in and day out. For this scenario, SCIEX recommends using the ExionLC 2.0+ system coupled to the X500R QTOF system, SCIEX OS software and maintenance with SCIEX service and support.
The workflow described in the technical note Targeted high-resolution metabolite screening workflows demonstrates the performance you can expect from this solution.

Scenario B
Suppose you have several samples where clear identification of the site of metabolism is not possible using CID. In this case, the use of a secondary analytical technique, such as nuclear magnetic resonance (NMR), is often required to meet regulatory requirements. Since this approach can be both time-consuming and expensive, an LC-MS system with more analytical power is ideal. Potent therapeutics is another common challenge in this type of scenario, which makes method sensitivity a key requirement for detecting low-abundant metabolites.

In these circumstances, SCIEX recommends using the ExionLC 2.0+ system coupled to the ZenoTOF 7600 system, SCIEX OS software and maintenance with SCIEX service and support.

The ZenoTOF 7600 system features the Zeno trap for enhanced sensitivity and electron activated dissociation (EAD) as a complementary fragmentation option. EAD typically fragments the metabolite in different locations, which can provide the additional information required for clear identification of the site of metabolism from a single analytical technique.

The workflow described in the technical note Confident characterization and identification of glucuronide metabolites using diagnostic fragments from electron activated dissociation (EAD) is a useful example of this solution.

Learn more
For more information on the options SCIEX offers for metID, please speak to your account manager or visit our web page on comprehensive metID.

Pure and simple: Understanding LNP analytics for better mRNA-based drugs

A few years ago, it was discovered that messenger RNA (mRNA) encapsulated in lipid nanoparticles (LNPs) could result in mRNA adducts due to the breakdown products of N-oxide impurities. The ionizable lipids used in LNPs are especially susceptible to forming N-oxide impurities.

Is the next life-changing drug waiting to be analyzed in your laboratory?

In drug discovery laboratories, there is often a need to generate trusted analytical data on hundreds of thousands of drug candidates to allow confident decisions to be made. Sample prep, instrument run time, and data processing are all challenges that must be overcome.

Mass spec data across the cultivated meat value chain

We recently had the opportunity to chat with Alex Ward, PhD, Principal Consultant, Arta Bioanalytics to discover more about his work in developing transcriptomics and metabolomics data interpretation for the cultivated meat sector. As a specialist in multi-omics approaches, Alex is driving R&D, production and regulatory processes for the industry. Below are Alex’s responses to a few questions we asked, sharing his knowledge with the SCIEX community to drive the future of cultivated meat.

Posted by

Kirsten Craven is the Senior Global Marketing Manager for Pharma global strategic marketing at SCIEX. In this role, she manages strategic marketing for the pharmaceutical industry. Kirsten spent the first part of her career working in laboratories across multiple industries before moving into product management, and most recently pharma marketing.

Tags


0 Comments

Submit a Comment

Social Share Buttons and Icons powered by Ultimatelysocial